Park Gil-Chun, Song Gi-Won, Moon Deok-Bog, Lee Sung-Gyu
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hepatobiliary Surg Nutr. 2016 Apr;5(2):107-17. doi: 10.3978/j.issn.2304-3881.2015.08.04.
Living donor liver transplantation (LDLT) has become an inevitable procedure in Asia due to its shortage of deceased donor under the influence of the religion and native cultures. Through a broad variety of experience, LDLT has been evolved and extended its indication. Although there have been many surgical and ethical efforts to prevent donor risk, concerns of donor's safety still are remaining questions due to its strict selection criteria. Therefore, dual grafts LDLT or ABO incompatible (ABO-I) LDLT may be effective means in its application and safety aspect. Many Asian LDLT centers have pointed out the useful extended criteria of LDLT for hepatocellular carcinoma (HCC), but the applicability of extended criteria should be validated and standardized by worldwide prospective studies based on the Milan criteria. Recent struggling efforts have been reported to surmount extensive portal vein thrombosis and Budd-Chiari syndrome which were previously contraindicated to LDLT. There is no doubt that LDLT is a surely complicated therapy to be performed successfully and requires devoted efforts by surgeons and co-workers. Nonetheless, comprehensive increasing understandings of partial graft LT and improvements of surgical techniques with challenges to obstacles in LDLT will make its prosperity with satisfactory outcomes.
由于宗教和本土文化的影响,亚洲已故供体短缺,活体供肝移植(LDLT)已成为一种必然的手术方式。通过广泛的经验积累,LDLT不断发展并扩大了其适应证。尽管为防止供体风险已经做出了许多手术和伦理方面的努力,但由于其严格的选择标准,供体安全问题仍然存在。因此,双供肝LDLT或ABO血型不相容(ABO-I)LDLT在应用和安全性方面可能是有效的手段。许多亚洲LDLT中心指出了LDLT用于肝细胞癌(HCC)的有用扩展标准,但扩展标准的适用性应通过基于米兰标准的全球前瞻性研究进行验证和标准化。最近有报道称,人们正在努力克服广泛的门静脉血栓形成和布加综合征,这些情况以前是LDLT的禁忌证。毫无疑问,LDLT是一种肯定复杂的治疗方法,要成功实施需要外科医生和同事们付出巨大努力。尽管如此,对部分肝移植的全面深入理解以及外科技术的改进,同时应对LDLT中的各种障碍,将使其取得令人满意的成果并蓬勃发展。